Tricyclic urea compounds as JAK2 V617F inhibitors
US12084430B2 · kind B2 · utility
0Cited by
25References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2023 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Mar 16, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.